A new oral antifungal (oteseconazole) specifically indicated for the treatment of RVVC was approved
in the United States in April 2022 and is currently on fast-track, priority review by Health Canada.
Leaders from the College of Family Physicians of Canada and its various provincial branches have outlined their priorities for addressing the primary care crisis as Canada's provincial premiers convene in Winnipeg this week.